ICU Medical (NASDAQ:ICUI) Issues FY 2024 Earnings Guidance

ICU Medical (NASDAQ:ICUI) issued an update on its FY 2024 earnings guidance on Tuesday morning. The company provided EPS guidance of 5.400-5.700 for the period, compared to the consensus EPS estimate of 5.220. The company issued revenue guidance of -. ICU Medical also updated its FY24 guidance to $5.40-5.70 EPS.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on ICUI. Raymond James lifted their target price on ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a report on Thursday, September 12th. Needham & Company LLC restated a “hold” rating on shares of ICU Medical in a report on Thursday, October 10th. Jefferies Financial Group began coverage on ICU Medical in a report on Monday, October 14th. They issued a “hold” rating and a $183.00 target price on the stock. KeyCorp lifted their target price on ICU Medical from $147.00 to $198.00 and gave the stock an “overweight” rating in a report on Tuesday, October 15th. Finally, StockNews.com upgraded ICU Medical from a “hold” rating to a “buy” rating in a report on Thursday, September 12th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $170.25.

ICU Medical Stock Down 0.1 %

Shares of ICU Medical stock traded down $0.26 during midday trading on Tuesday, hitting $178.01. The company’s stock had a trading volume of 267,471 shares, compared to its average volume of 273,286. The firm has a market capitalization of $4.35 billion, a P/E ratio of -61.05 and a beta of 0.66. ICU Medical has a 1-year low of $79.85 and a 1-year high of $188.53. The company has a quick ratio of 1.08, a current ratio of 2.41 and a debt-to-equity ratio of 0.76. The stock has a 50-day simple moving average of $175.56 and a 200-day simple moving average of $141.16.

Insider Activity at ICU Medical

In related news, CEO Vivek Jain sold 12,000 shares of ICU Medical stock in a transaction on Friday, August 16th. The stock was sold at an average price of $156.04, for a total transaction of $1,872,480.00. Following the completion of the sale, the chief executive officer now owns 104,593 shares of the company’s stock, valued at approximately $16,320,691.72. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other ICU Medical news, CEO Vivek Jain sold 12,000 shares of the business’s stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $156.04, for a total value of $1,872,480.00. Following the completion of the sale, the chief executive officer now owns 104,593 shares of the company’s stock, valued at $16,320,691.72. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Daniel Woolson sold 2,502 shares of the business’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $163.22, for a total value of $408,376.44. Following the completion of the sale, the vice president now directly owns 13,107 shares of the company’s stock, valued at $2,139,324.54. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 50,502 shares of company stock valued at $8,445,976. Insiders own 6.70% of the company’s stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.